241 related articles for article (PubMed ID: 26686090)
1. FOXP3 can modulate TAL1 transcriptional activity through interaction with LMO2.
Fleskens V; Mokry M; van der Leun AM; Huppelschoten S; Pals CE; Peeters J; Coenen S; Cardoso BA; Barata JT; van Loosdregt J; Coffer PJ
Oncogene; 2016 Aug; 35(31):4141-8. PubMed ID: 26686090
[TBL] [Abstract][Full Text] [Related]
2. Angiopoietin-2 is a direct transcriptional target of TAL1, LYL1 and LMO2 in endothelial cells.
Deleuze V; El-Hajj R; Chalhoub E; Dohet C; Pinet V; Couttet P; Mathieu D
PLoS One; 2012; 7(7):e40484. PubMed ID: 22792348
[TBL] [Abstract][Full Text] [Related]
3. A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice.
Draheim KM; Hermance N; Yang Y; Arous E; Calvo J; Kelliher MA
Oncogene; 2011 Mar; 30(10):1252-60. PubMed ID: 21057528
[TBL] [Abstract][Full Text] [Related]
4. Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.
McCormack MP; Shields BJ; Jackson JT; Nasa C; Shi W; Slater NJ; Tremblay CS; Rabbitts TH; Curtis DJ
Blood; 2013 Sep; 122(12):2093-103. PubMed ID: 23926305
[TBL] [Abstract][Full Text] [Related]
5. NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1-expressing human T cell acute lymphoblastic leukemia.
Kusy S; Gerby B; Goardon N; Gault N; Ferri F; Gérard D; Armstrong F; Ballerini P; Cayuela JM; Baruchel A; Pflumio F; Roméo PH
J Exp Med; 2010 Sep; 207(10):2141-56. PubMed ID: 20855495
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous rearrangements of TAL1 and LMO2 in T-cell acute lymphoblastic leukemia.
Kim HK; Lim JH; Koh KN; Chi HS; Seo EJ
Int J Lab Hematol; 2014 Oct; 36(5):e69-70. PubMed ID: 24330618
[No Abstract] [Full Text] [Related]
7. The NUP98-HOXD13 fusion oncogene induces thymocyte self-renewal via Lmo2/Lyl1.
Shields BJ; Slape CI; Vo N; Jackson JT; Pliego-Zamora A; Ranasinghe H; Shi W; Curtis DJ; McCormack MP
Leukemia; 2019 Aug; 33(8):1868-1880. PubMed ID: 30700838
[TBL] [Abstract][Full Text] [Related]
8. Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex.
El Omari K; Hoosdally SJ; Tuladhar K; Karia D; Vyas P; Patient R; Porcher C; Mancini EJ
Blood; 2011 Feb; 117(7):2146-56. PubMed ID: 21076045
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional activity of TAL1 in T cell acute lymphoblastic leukemia (T-ALL) requires RBTN1 or -2 and induces TALLA1, a highly specific tumor marker of T-ALL.
Ono Y; Fukuhara N; Yoshie O
J Biol Chem; 1997 Feb; 272(7):4576-81. PubMed ID: 9020185
[TBL] [Abstract][Full Text] [Related]
10. TAL1 as a master oncogenic transcription factor in T-cell acute lymphoblastic leukemia.
Sanda T; Leong WZ
Exp Hematol; 2017 Sep; 53():7-15. PubMed ID: 28652130
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a pediatric T-cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements.
Homminga I; Vuerhard MJ; Langerak AW; Buijs-Gladdines J; Pieters R; Meijerink JP
Haematologica; 2012 Feb; 97(2):258-61. PubMed ID: 22058201
[TBL] [Abstract][Full Text] [Related]
12. TAL1 and LIM-only proteins synergistically induce retinaldehyde dehydrogenase 2 expression in T-cell acute lymphoblastic leukemia by acting as cofactors for GATA3.
Ono Y; Fukuhara N; Yoshie O
Mol Cell Biol; 1998 Dec; 18(12):6939-50. PubMed ID: 9819382
[TBL] [Abstract][Full Text] [Related]
13. Aberrant TAL1 activation is mediated by an interchromosomal interaction in human T-cell acute lymphoblastic leukemia.
Patel B; Kang Y; Cui K; Litt M; Riberio MS; Deng C; Salz T; Casada S; Fu X; Qiu Y; Zhao K; Huang S
Leukemia; 2014 Feb; 28(2):349-61. PubMed ID: 23698277
[TBL] [Abstract][Full Text] [Related]
14. Assembly of the oncogenic DNA-binding complex LMO2-Ldb1-TAL1-E12.
Ryan DP; Duncan JL; Lee C; Kuchel PW; Matthews JM
Proteins; 2008 Mar; 70(4):1461-74. PubMed ID: 17910069
[TBL] [Abstract][Full Text] [Related]
15. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia.
Mansour MR; Sanda T; Lawton LN; Li X; Kreslavsky T; Novina CD; Brand M; Gutierrez A; Kelliher MA; Jamieson CH; von Boehmer H; Young RA; Look AT
J Exp Med; 2013 Jul; 210(8):1545-57. PubMed ID: 23857984
[TBL] [Abstract][Full Text] [Related]
16. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
[TBL] [Abstract][Full Text] [Related]
17. Ldb1 is required for Lmo2 oncogene-induced thymocyte self-renewal and T-cell acute lymphoblastic leukemia.
Li L; Mitra A; Cui K; Zhao B; Choi S; Lee JY; Stamos DB; El-Khoury D; Warzecha C; Pfeifer K; Hardwick J; Zhao K; Venters B; Davé UP; Love PE
Blood; 2020 Jun; 135(25):2252-2265. PubMed ID: 32181817
[TBL] [Abstract][Full Text] [Related]
18. The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells.
Valge-Archer VE; Osada H; Warren AJ; Forster A; Li J; Baer R; Rabbitts TH
Proc Natl Acad Sci U S A; 1994 Aug; 91(18):8617-21. PubMed ID: 8078932
[TBL] [Abstract][Full Text] [Related]
19. LMO2 is required for TAL1 DNA binding activity and initiation of definitive haematopoiesis at the haemangioblast stage.
Stanulovic VS; Cauchy P; Assi SA; Hoogenkamp M
Nucleic Acids Res; 2017 Sep; 45(17):9874-9888. PubMed ID: 28973433
[TBL] [Abstract][Full Text] [Related]
20. PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events.
Mendes RD; Sarmento LM; Canté-Barrett K; Zuurbier L; Buijs-Gladdines JG; Póvoa V; Smits WK; Abecasis M; Yunes JA; Sonneveld E; Horstmann MA; Pieters R; Barata JT; Meijerink JP
Blood; 2014 Jul; 124(4):567-78. PubMed ID: 24904117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
